Sodium–Glucose Cotransporter 2 Inhibition in Diabetic Macular Oedema: Emerging Evidence for Stage‐Dependent Systemic‐Retinal Responsiveness
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 10992-11005
DOI: 10.1111/dom.71295 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 02.09.2026. Verfasst von Ryoichi Ishibashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Macular Edema, Sodium-Glucose Transporter 2 Inhibitors, Retina. Die Arbeit nennt 73 Literaturangaben. Gefördert von: Astellas Pharma Inc., Taisho Pharmaceutical Co. Ltd..
Abstract (Originalsprache)
Aims
Sodium‐glucose cotransporter 2 (SGLT2) inhibitors exert systemic cardiometabolic, renal and vascular effects that may influence retinal health, yet whether their effects on diabetic macular oedema (DMO) are stage‐dependent remains unclear. We synthesized real‐world, interventional and mechanistic evidence on responsiveness across disease stages and retinal phenotypes. Materials and Methods In this scoping review (PRISMA‐ScR; prospectively registered, UMIN000061304), we searched PubMed, the Cochrane Library, ClinicalTrials.gov , WHO‐ICTRP and Google Scholar for studies published from January 2014 to April 2026. Two reviewers independently screened and charted records. Heterogeneity precluded meta‐analysis, so a qualitative meta‐summary with exploratory E‐value analyses was performed.
Results
Forty studies were included. Large administrative databases consistently associated SGLT2 inhibitor use with a 16%–35% lower DMO incidence (hazard ratio 0.65–0.84) and hazard ratios of 0.53–0.94 for diabetic retinopathy progression. In established DMO, observational studies reported hazard ratios of 0.39–0.81 for anti‐vascular endothelial growth factor (VEGF) injections, corticosteroid therapy and repeat vitrectomy, with the first‐vitrectomy estimate non‐significant, and attenuation in severe non‐proliferative or proliferative retinopathy. The only randomized trial (COMET) did not meet its primary endpoint; its fellow‐eye and phenotype‐specific subgroup analyses were exploratory and hypothesis‐generating. Proposed mechanisms include suppression of microglial activation, oxidative stress and angiopoietin‐2/VEGF signalling, although translational evidence remains preclinical.
Conclusions
This predominantly observational evidence suggests that SGLT2 inhibitors may be associated with slower DMO disease kinetics across retinopathy stages, with reduced treatment burden most evident before severe retinopathy. Systemic SGLT2 inhibition may complement, rather than replace, anti‐VEGF therapy, which remains the cornerstone of DMO management. These findings support prospective stage‐ and phenotype‐stratified investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
- Department of Endocrinology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan.
- Department of Nutrition and Metabolic Medicine, Center for Preventive Medical Sciences, Chiba University, Chiba, Chiba, Japan.
- Department of Ophthalmology and Vision Science, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan.
- Department of Ophthalmology, Chiba Rosai Hospital, Ichihara, Chiba, Japan.
ORCID-Profile: Ryoichi Ishibashi, Kiichi Hirayama, Masaya Koshizaka, Koutaro Yokote
Förderung
- Astellas Pharma Inc.
- Taisho Pharmaceutical Co. Ltd.
Zitieren
APA
Ishibashi, R., Hirayama, K., Sakai, T., Tatsumi, T., Takatsuna, Y., Baba, T., Koshizaka, M., & Yokote, K. (2026). Sodium–Glucose Cotransporter 2 Inhibition in Diabetic Macular Oedema: Emerging Evidence for Stage‐Dependent Systemic‐Retinal Responsiveness. Diabetes, Obesity and Metabolism, 28(12), 10992-11005. https://doi.org/10.1111/dom.71295
Vancouver
Ishibashi R, Hirayama K, Sakai T, Tatsumi T, Takatsuna Y, Baba T, et al. Sodium–Glucose Cotransporter 2 Inhibition in Diabetic Macular Oedema: Emerging Evidence for Stage‐Dependent Systemic‐Retinal Responsiveness. Diabetes, Obesity and Metabolism. 2026;28(12):10992-11005. doi:10.1111/dom.71295
BibTeX
@article{Ishibashi2026,
author = {Ishibashi, Ryoichi and Hirayama, Kiichi and Sakai, Toshiki and Tatsumi, Tomoaki and Takatsuna, Yoko and Baba, Takayuki and Koshizaka, Masaya and Yokote, Koutaro},
title = {Sodium–Glucose Cotransporter 2 Inhibition in Diabetic Macular Oedema: Emerging Evidence for Stage‐Dependent Systemic‐Retinal Responsiveness},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {12},
pages = {10992--11005},
doi = {10.1111/dom.71295}
}
EUVIMED